Gilead Sciences reported adjusted earnings of $2.12 per share, slightly up from last year, but slashed its full-year forecast from $4.70-$5.20 to $3-$3.50 after a substantial $2.7 billion impairment charge related to Immunomedics. The company's revenue rose to $6.6 billion, driven by sales of its COVID-19 treatment, Veklury, yet Gilead missed earnings expectations by 54.9%. As a result, Gilead's shares have fallen, signaling investor concern amid strong drug performance.
“Gilead Sciences, Inc. · reported · adjusted earnings · $2.12 per share”
“Gilead Sciences, Inc. · anticipated · earnings · in the range of $3 - $3.50 per share”
“Gilead Sciences (GILD) · released data demonstrating the effectiveness of remdesivir · ten Covid-19 variants · true”
“Gilead Sciences (GILD) · said that the Food and Drug Administration granted a label expansion for Yescarta · its first CAR T-cell therapy · true”
“Gilead Sciences · gets very little attention for its drug developments”
“Gilead · released data demonstrating the effectiveness of remdesivir · against ten Covid-19 variants”
“Gilead Sciences, Inc. · reported · adjusted earnings · $2.12 per share”
“Gilead Sciences, Inc. · reported · revenue · $6.6 billion”
“Gilead Sciences, Inc. · reported · adjusted earnings · $2.12 per share”
“Gilead Sciences, Inc. · slashed its earnings outlook · for the full year · $3 - $3.50 per share”
“Gilead Sciences Inc. · is slated to report · first-quarter 2022 results · on Apr 28, after market close”
“Gilead Sciences Inc. · has a track record of · earnings beating estimates · in three of the last four quarters”
